GlaxoSmithKline plc (GSK) Updates on Tafinlar Survival Rates from Phase III BREAK-3
Tweet Send to a Friend
GlaxoSmithKline plc (NYSE: GSK) announced updated results for Tafinlar (dabrafenib) from a planned analysis of the phase III BREAK-3 study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
